Business & Decision Life Sciences has been identified as one of the verticals with the most growth potential within the Business & Decision Group. To continue to be successful, operational excellence and innovation will become even more critical in the years to come.To support these goals, Xavier Gobert and Peter Van Reusel have been assigned to take on strategic roles in the international Life Sciences organization.
As of July 1st, Xavier Gobert will assume the role of Chief Strategy Officer and Peter Van Reusel will assume the role of Chief Operational Officer. Both have proven outstanding operational excellence over the past years.Business & Decision Life Sciences will focus on leveraging the technological expertise and strong drive for innovation of the Business & Decision Group.
To this end, an Executive Committee will be installed where Xavier and Peter will be joined Patrick Bensabat, CEO of the Business & Decision Group and Ada Sekirin, VP Innovations to identify new areas of development. Business & Decision Life Sciences have identified the need to seek industry advice to identify future opportunities, business needs and trends within the healthcare industry. Industry thought leaders from Pharmaceutical Companies, Regulatory Agencies and Healthcare stakeholders will be invited to participate in a dedicated Industry Advisory Board.
We are also taking the opportunity to announce that Jerry Welkenhuysen-Gybels has decided to seek opportunities outside the company. We would like to thank Jerry for his strong commitment to the organizational growth of Business & Decision Life Sciences, and this to bring it up to the level of maturity it is at today.